A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered GLPG3667 Once Daily for 24 Weeks in Adult Subjects With Dermatomyositis
Latest Information Update: 27 May 2025
At a glance
- Drugs GLPG 3667 (Primary)
- Indications Dermatomyositis
- Focus Therapeutic Use
- Acronyms GALARISSO
- Sponsors Galapagos NV
Most Recent Events
- 18 May 2025 Planned End Date changed from 1 Jun 2026 to 1 Apr 2026.
- 18 May 2025 Planned primary completion date changed from 1 Jan 2026 to 1 Oct 2025.
- 18 May 2025 Status changed from recruiting to active, no longer recruiting.